Intravitreal Injections: Age-related macular degeneration
What is age related macular degeneration?
Age-related macular degeneration is the leading cause of loss of sight in those over the age of 60 years. Various treatment options are available. You can find out more about the condition here
When are intravitreal injections indicated?
Age-related macular degeneration is associated with release of growth factors including vascular endothelial growth factor (VEGF) which causes blood vessels in the eye to leak and also produce new vessels called macular neovascularisation which can cause a bleed inside the central part of the eye.
Anti-VEGF injections will block the VEGF growth factor and improve the leakage of fluid and prevent further complications such as bleeding inside the eye.
Will intravitreal injections improve vision?
The aim of intravitreal anti-VEGF injections is to stabilise vision in 90-95% of patients with a 30% chance of improving vision by 2 lines on the vision chart or 10 letters on the ETDRS vision chart. Without treatment, there is 1:2 chance of vision remaining the same without getting worse.
What are the risks of intravitreal injections?
The risks for steroid eye injections include 1:3000 chance of severe visual loss, seeing floaters for a few days, mild redness, grittiness and discomfort.
Our Consultants at VISIO Health have the expertise in treating age-related macular degeneration and will help you decide in which treatment option is best for you.
Our Treatments and Price List
| Avastin eye injection | £750 |
| Lucentis eye injection | £1700 |
| Eylea eye injection | £1800 |
| Vabysmo eye injection | £1950 |
If you would like to discuss Ophthalmology treatments, please get in touch with a member of our team
